Vol. 6 No. 5 (2026): May
Reimbursement Reviews

Osilodrostat (Isturisa)

decorative image of the issue cover

Published May 7, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Osilodrostat (Isturisa), 1 mg, 5 mg, 10 mg, film-coated tablets, oral.
  • Indication: For the treatment of adult patients with Cushing’s disease who have persistent or recurrent hypercortisolism after primary pituitary surgery and/or irradiation, or for whom pituitary surgery is not an option.